Back to search results
NCT06774144

Rezafungin Prophylaxis in Liver Transplant

Enrolling by Invitation
PHASE3Ages 18+InterventionalPrevention
Fernanda P Silveira, MD, MS
~385 participants
Updated 2025-10-20 on ClinicalTrials.gov
What's tested:RezafunginStandard of care antifungal prophylaxis

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of proven and probable IFIs
Measured over 90 days post-transplant
+1 more outcome measured

Conditions

Liver Transplant Infection
Fungal Infection

Explore related trials

Fungal InfectionLiver Transplantation

Where it's being run

1 sites across 1 states
Pennsylvania1

Study leadership

  • Fernanda Silveira · PRINCIPAL_INVESTIGATOR · University of Pittsburgh

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Liver transplant recipient
18 years of age or older
≥1 risk factor(s) for IFI: living donor transplant, retransplantation, complicated operations (based on duration of transplant and number of blood products required in the peri-transplant period), choledochojejunostomy anastomosis, or peri-operative Candida colonization, recent Candida infection, renal replacement therapy post-transplant, and reoperation within the first 90 days of transplant.

Exclusion

Participants who are perceived not to survive past 7 days after transplant
Participants who elect not to participate in the prospective trial
Participants who had active candidiasis at the time of transplant
Participants with a history of allergy to an echinocandin
Participants who are pregnant.

What this trial measures

  • Incidence of proven and probable IFIs90 days post-transplant

    Incidence of proven and probable IFIs within 90 days post-transplant

  • Incidence of proven and probable breakthrough IFIWhile receiving rezafungin, voriconazole, or fluconazole

    Incidence of breakthrough IFI while on specific antifungal prophylaxis